It has been reported that elevated B2M can worsen the prognosis of patients with renal cell carcinoma [45], prostate cancer, breast cancer [29], hematological malignancy [30, 31, 46–48] and glioma [49]. This evidence concerns the gene B2M and prostate cancer.